{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-006866","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.869018+00:00","generated_at":"2026-05-22T05:20:59.092040+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dogwood Therapeutics Q1 2025 net loss $12.2M; Halneuron Phase 2b dosing underway","bullets":["Net loss of $12.2M ($8.45 per share) vs $1.3M ($1.68) in Q1 2024; R&D spend rose to $2.4M.","Halneuron Phase 2b CINP study initiated; interim data readout expected Q4 2025.","$19.5M loan from CK Life Sciences affiliate converted to equity; $4.8M gross common stock raise.","Cash and equivalents of $17.5M provides operational runway through Q1 2026.","Regained Nasdaq compliance with minimum stockholders' equity of $2.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-006866","json":"https://secwatch.observer/filing/0001558370-25-006866.json","markdown":"https://secwatch.observer/filing/0001558370-25-006866.md","text":"https://secwatch.observer/filing/0001558370-25-006866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837025006866/0001558370-25-006866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837025006866/dwtx-20250508x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:20:59.092040+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}